A new drug for the treatment of interstitial cystitis has been registered
Mirpharm Announces Successful Registration of Miropentane, the Only FDA Approved Oral Drug
Moscow, July 2022
Mirpharm has successfully completed the registration of a new drug, Miropentane, the only FDA-approved oral drug
Miropentane (INN - pentosan sodium polysulfate) is used in the treatment of interstitial cystitis and has a long-term anti-inflammatory effect and pain relief, proven in national and international clinical studies.
It is the only oral drug approved by the FDA and is the first line of treatment for painful bladder syndrome in clinical guidelines.
Miropentan is also the only officially registered drug for the treatment of interstitial cystitis in Russia.
The drug restores the inner surface of the bladder - the urothelium, thus protecting the bladder from toxic irritating substances contained in the urine.
The course of treatment with this drug is 3-6 months, after which there is an improvement.
Mirpharm is an international group of companies with its own R&D centers and production facilities in Russia and the European Union.